DECIPHERING THE GENETIC ARCHITECTURE OF PARKINSON’S DISEASE IN THE LUXEMBOURGISH POPULATION

Parkinson's Disease (PD) is the fastest-growing neurodegenerative disorder (Bloem et al., 2021; Dorsey et al., 2018). It is characterized by motor symptoms such as postural instability, rest tremor, bradykinesia and rigidity (Kalia and Lang, 2015). Additionally, PD exhibits non-motor symptoms including cognitive impairment, neuropsychiatric features like hallucinations, depression, and anxiety, as well as sleep disturbances, hyposmia and autonomic dysfunction (Khoo et al., 2013). While the exact causes of PD remain incompletely understood, research has identified genetic risk factors as import... Mehr ...

Verfasser: PACHCHEK, Sinthuja
Dokumenttyp: doctoral thesis
Erscheinungsdatum: 2023
Verlag/Hrsg.: Unilu - University of Luxembourg
Schlagwörter: GBA1 / glucocerebrosidase / Parkinson’s disease / Genetics / long-read sequencing / Life sciences / Genetics & genetic processes / Sciences du vivant / Génétique & processus génétiques
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-29525745
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://orbilu.uni.lu/handle/10993/58225

Parkinson's Disease (PD) is the fastest-growing neurodegenerative disorder (Bloem et al., 2021; Dorsey et al., 2018). It is characterized by motor symptoms such as postural instability, rest tremor, bradykinesia and rigidity (Kalia and Lang, 2015). Additionally, PD exhibits non-motor symptoms including cognitive impairment, neuropsychiatric features like hallucinations, depression, and anxiety, as well as sleep disturbances, hyposmia and autonomic dysfunction (Khoo et al., 2013). While the exact causes of PD remain incompletely understood, research has identified genetic risk factors as important contributing factors in its development. Although PD appears typically as sporadic, approximately 30% of cases can be linked to genetic factors involving monogenic forms (Billingsley et al., 2018). Although motor symptoms can be effectively addressed by pharmacological therapies at least in early disease stages, there is currently no treatment that may interfere with the chronic progressive neurodegeneration. Therefore, there is a strong motivation among clinicians and researchers to perform early diagnoses and identify genetic variants that could lead to future causative and thereby neuroprotective therapies. However, PD is a complex disorder influenced by a combination of environmental and genetic factors. Only a limited subset of genes have been conclusively associated with typical PD, as their causative role in Mendelian forms of PD has been consistently replicated in multiple studies involving large populations of PD patients (Bandres-Ciga et al., 2020). These rare Mendelian forms follow distinct inheritance patterns and have a notable impact on disease development (e.g., SNCA, LRRK2, VPS35, PRKN, PINK1 and PARK7). There are also low-frequency variants with significant effects, such as the GBA1 and LRRK2 genes. These variants are not as rare as monogenic mutations, but their frequency remains relatively low in the general population. Then, there are the common variants that exert minor effects and highlight genetic ...